Medicenna Expands IP Portfolio with Five New Patents for Superkines

An update from Medicenna Therapeutics Corp ( (TSE:MDNA) ) is now available.

Medicenna Therapeutics Corp has announced the granting of five new patents that bolster its intellectual property portfolio for IL-2 and IL-4 Superkine platforms. These patents, covering composition, formulation, and therapeutic applications, enhance Medicenna’s market position by securing long-term protection and commercial potential for its key clinical and preclinical programs. The patents span major global markets and support the ongoing development of MDNA11 and bizaxofusp, reinforcing the company’s competitive advantage and shareholder value.

The most recent analyst rating on (TSE:MDNA) stock is a Buy with a C$3.75 price target. To see the full list of analyst forecasts on Medicenna Therapeutics Corp stock, see the TSE:MDNA Stock Forecast page.

Spark’s Take on TSE:MDNA Stock

According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.

Medicenna Therapeutics Corp. receives a moderate overall score, reflecting its financial challenges and reliance on financing. However, positive results from clinical trials and promising preclinical data provide notable upside potential. Technical indicators are neutral, offering a balanced view of near-term stock performance. Valuation highlights the speculative nature typical of biotech stocks, while recent corporate events significantly bolster future growth prospects.

To see Spark’s full report on TSE:MDNA stock, click here.

More about Medicenna Therapeutics Corp

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, as well as first-in-class Empowered Superkines. The company is engaged in creating next-generation therapies for oncology and autoimmune diseases, with products like MDNA11 and bizaxofusp (MDNA55) being key components of its clinical pipeline.

Average Trading Volume: 28,296

Technical Sentiment Signal: Sell

Current Market Cap: C$58.39M

For an in-depth examination of MDNA stock, go to TipRanks’ Overview page.